23 Jul, 2026
According to Straits Research, the global point-of-care infectious disease testing market was valued at USD 13.83 billion in 2025 and is projected to grow from USD 14.46 billion in 2026 to USD 21.32 billion by 2034, registering a CAGR of 4.97% during the forecast period (2026–2034).
The market is witnessing steady growth due to the rising prevalence of infectious diseases, increasing demand for rapid and decentralized diagnostic solutions, and continuous advancements in portable testing technologies. The growing adoption of molecular diagnostics, rapid antigen tests, and point-of-care testing devices across hospitals, clinics, pharmacies, and home-care settings is improving early disease detection and supporting timely treatment decisions. In addition, increasing healthcare investments, expanding disease surveillance programs, and the rising focus on accessible and cost-effective diagnostics are expected to further drive market growth during the forecast period.
The growth of the point-of-care infectious disease testing market is primarily driven by the increasing global burden of infectious diseases and the rising adoption of decentralized diagnostic models aimed at early detection and containment. The growing emphasis on preventive healthcare, coupled with government-led screening programs and the availability of portable molecular testing devices, is accelerating the shift toward rapid, near-patient testing across hospitals, clinics, and community health settings. However, market expansion is restrained by variability in test performance across decentralized environments, where inconsistencies in sample collection, limited operator training, and a lack of standardized validation protocols can affect diagnostic accuracy and clinical reliability. Despite these challenges, the market presents a strong opportunity in the integration of POC diagnostics with digital health ecosystems and telemedicine platforms, enabling remote result interpretation, real-time disease surveillance, and improved patient engagement through connected and data-driven healthcare solutions.
North America held the largest share of the global point-of-care infectious disease testing market in 2025, accounting for 53.47% of the total revenue. The region's dominance is attributed to its advanced healthcare infrastructure, widespread adoption of rapid diagnostic technologies, favorable reimbursement policies, and strong government initiatives for infectious disease surveillance. The presence of leading diagnostic manufacturers and continuous investments in research and development further support market growth across the region.
Asia-Pacific is expected to register the fastest CAGR of 6.97% during the forecast period. The region's growth is driven by expanding healthcare infrastructure, increasing government spending on public health, rising awareness of early disease diagnosis, and growing demand for affordable point-of-care testing solutions. Rapid urbanization, a large patient population, and the increasing adoption of portable diagnostic devices in countries such as China, India, Japan, and South Korea are expected to further accelerate market expansion.
sales@straitsresearch.com